The changing definition of Alzheimer's disease

To address these concerns, the IWG advocates a return to Alzheimer's disease as a clinical-biological entity, characterised by amyloid β and tau biomarkers plus a typical clinical phenotype. Dubois and colleagues advise against measurement of amyloid β and tau biomarkers in asymptomatic people...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology 2021-06, Vol.20 (6), p.414-415
Main Author: Jagust, William J
Format: Article
Language:English
Subjects:
Alzheimer's disease
Asymptomatic
Biomarkers
Dementia
Neurodegenerative diseases
Neuropathology
Pathology
Phenotypes
Tau protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To address these concerns, the IWG advocates a return to Alzheimer's disease as a clinical-biological entity, characterised by amyloid β and tau biomarkers plus a typical clinical phenotype. Dubois and colleagues advise against measurement of amyloid β and tau biomarkers in asymptomatic people because of unreliable predictive power; nevertheless, these authors do provide a risk stratification scheme for such people, and abnormal amyloid β and tau biomarkers are thought to confer high risk. The research framework7 does not provide clear guidance for a clinician about prognosis, but as longitudinal studies continue, evidence is accumulating that, at least in some cohorts, amyloid β and tau are malignant.9,10 Longer longitudinal follow-up in representative samples are needed for better understanding of these biomarkers.
ISSN:1474-4422
1474-4465
DOI:10.1016/S1474-4422(21)00077-6